Skip to main content

Are you Dr. Porteus?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 44 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Matthew Porteus, MD is a pediatric hematologist/oncologist in Dallas, Texas. He is currently licensed to practice medicine in Texas and California. He is affiliated with Lucile Packard Children's Hospital Stanford and Stanford Health Care.

Education & Training

  • Children's Hospital/Boston Medical Center
    Children's Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1996 - 1999
  • Children's Hospital/Boston Medical Center
    Children's Hospital/Boston Medical CenterResidency, Pediatrics, 1994 - 1996
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 1994

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2000 - 2023
  • TX State Medical License
    TX State Medical License 2003 - 2011
  • American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Hit Pause: The Read-Across to Graphite Bio’s CEDAR Sickle Cell Trial Suspension
    Hit Pause: The Read-Across to Graphite Bio’s CEDAR Sickle Cell Trial SuspensionJanuary 26th, 2023
  • Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
    Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell DiseaseAugust 11th, 2022
  • Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition
    Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and ExpositionDecember 11th, 2021
  • Join now to see all

Grant Support

  • Using Zinc Finger Nucleases To Stimulate Gene Targeting In HSCNational Heart, Lung, And Blood Institute2006–2009
  • Zinc Finger Nucleases To Stimulate Gene Targeting In Hematopoietic Stem CellsNational Heart, Lung, And Blood Institute2007
  • Development Of Gene Targeting In C. Elegans And D. Rerio Using Zinc FingerNational Cancer Institute2006–2007
  • The Genetics Of Gene Targeting In Vertebrate CellsNational Heart, Lung, And Blood Institute2003–2006
  • The Genetics Of Gene Targeting In Vertebrate CellsNational Heart, Lung, And Blood Institute2002

Hospital Affiliations